173 related articles for article (PubMed ID: 38411275)
1. Metabolism-focused CRISPR screen unveils mitochondrial pyruvate carrier 1 as a critical driver for PARP inhibitor resistance in lung cancer.
Furusawa T; Cavero R; Liu Y; Li H; Xu X; Andresson T; Reinhold W; White O; Boufraqech M; Meyer TJ; Hartmann O; Diefenbacher ME; Pommier Y; Weyemi U
Mol Carcinog; 2024 Jun; 63(6):1024-1037. PubMed ID: 38411275
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
3. Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
Jette NR; Radhamani S; Arthur G; Ye R; Goutam S; Bolyos A; Petersen LF; Bose P; Bebb DG; Lees-Miller SP
Br J Cancer; 2019 Oct; 121(7):600-610. PubMed ID: 31481733
[TBL] [Abstract][Full Text] [Related]
4. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
[TBL] [Abstract][Full Text] [Related]
5. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
6. Genome-scale CRISPR knockout screen identifies
Fang P; De Souza C; Minn K; Chien J
Commun Biol; 2019; 2():335. PubMed ID: 31508509
[TBL] [Abstract][Full Text] [Related]
7. CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions.
Zimmermann M; Murina O; Reijns MAM; Agathanggelou A; Challis R; Tarnauskaitė Ž; Muir M; Fluteau A; Aregger M; McEwan A; Yuan W; Clarke M; Lambros MB; Paneesha S; Moss P; Chandrashekhar M; Angers S; Moffat J; Brunton VG; Hart T; de Bono J; Stankovic T; Jackson AP; Durocher D
Nature; 2018 Jul; 559(7713):285-289. PubMed ID: 29973717
[TBL] [Abstract][Full Text] [Related]
8. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of BAD-Ser99 phosphorylation synergizes with PARP inhibition to ablate PTEN-deficient endometrial carcinoma.
Zhang X; Huang P; Wang L; Chen S; Basappa B; Zhu T; Lobie PE; Pandey V
Cell Death Dis; 2022 Jun; 13(6):558. PubMed ID: 35725817
[TBL] [Abstract][Full Text] [Related]
10. PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer.
Jiang Y; Dai H; Li Y; Yin J; Guo S; Lin SY; McGrail DJ
Int J Cancer; 2019 Mar; 144(5):1092-1103. PubMed ID: 30152517
[TBL] [Abstract][Full Text] [Related]
11. ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination-deficient cells.
Verma P; Zhou Y; Cao Z; Deraska PV; Deb M; Arai E; Li W; Shao Y; Puentes L; Li Y; Patankar S; Mach RH; Faryabi RB; Shi J; Greenberg RA
Nat Cell Biol; 2021 Feb; 23(2):160-171. PubMed ID: 33462394
[TBL] [Abstract][Full Text] [Related]
12. BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repair.
Kong Y; Xu C; Sun X; Sun H; Zhao X; He N; Ji K; Wang Q; Du L; Wang J; Zhang M; Liu Y; Wang Y; Liu Q
Cancer Biol Med; 2021 Dec; 19(8):1150-71. PubMed ID: 34846107
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression.
Ma X; Dang C; Min W; Diao Y; Hui W; Wang X; Dai Z; Wang X; Kang H
Breast Cancer Res Treat; 2019 Jul; 176(1):109-117. PubMed ID: 30989461
[TBL] [Abstract][Full Text] [Related]
14. PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports.
Collot T; Niogret J; Carnet M; Chevrier S; Humblin E; Favier L; Bengrine-Lefevre L; Desmoulins I; Arnould L; Boidot R
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33236159
[TBL] [Abstract][Full Text] [Related]
15. Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.
Murai J; Feng Y; Yu GK; Ru Y; Tang SW; Shen Y; Pommier Y
Oncotarget; 2016 Nov; 7(47):76534-76550. PubMed ID: 27708213
[TBL] [Abstract][Full Text] [Related]
16. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
[TBL] [Abstract][Full Text] [Related]
17. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
[TBL] [Abstract][Full Text] [Related]
18. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
19. Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage.
Giovannini S; Weller MC; Repmann S; Moch H; Jiricny J
Nucleic Acids Res; 2019 Sep; 47(17):9132-9143. PubMed ID: 31329989
[TBL] [Abstract][Full Text] [Related]
20. Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma.
Watson ZL; Yamamoto TM; McMellen A; Kim H; Hughes CJ; Wheeler LJ; Post MD; Behbakht K; Bitler BG
Clin Epigenetics; 2019 Nov; 11(1):165. PubMed ID: 31775874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]